Quarterly ResultAug 13, 2026, 04:10 PM
Co-Diagnostics Q2 Net Loss $6.3M; Submits FDA 510(k)
AI Summary
Co-Diagnostics, Inc. reported its second quarter 2026 financial results, with revenue increasing slightly to $0.17 million and net loss improving to $6.3 million, or $1.46 per share, compared to the prior year. The company also announced significant operational progress, including the submission of its FDA 510(k) application for the Co-Dx PCR Flu A/B & RSV test and a $3.0 million private placement. Strategic advancements were made in manufacturing, global commercialization, and product pipeline development.
Key Highlights
- Revenue increased to $0.17 million in Q2 2026 from $0.16 million in Q2 2025.
- Net loss decreased to $6.3 million, or $1.46 per share, in Q2 2026 from $7.7 million, or $7.00 per share, in Q2 2025.
- Operating expenses decreased to $6.3 million in Q2 2026 from $8.2 million in Q2 2025.
- Adjusted EBITDA loss improved to $5.8 million in Q2 2026 from $7.2 million in Q2 2025.
- Cash and cash equivalents totaled $3.6 million as of June 30, 2026.
- Submitted FDA 510(k) application for Co-Dx PCR Flu A/B & RSV test on Co-Dx PCR Pro instrument.
- Completed a $3.0 million private placement to strengthen the balance sheet.
- Advanced manufacturing strategy in Saudi Arabia and expanded commercial outreach in Europe and Latin America.
Price Impact
More from CODX